Special Issue

Application of Brachytherapy in Clinical Practice

Message from the Guest Editors

Brachytherapy (or interventional radiotherapy) is a wellestablished radiotherapy technique with a long history of experience and successful applications. In recent years, there have been a lot of innovations in radiotherapy which included the introduction of hybrid machines. IGRT techniques, and high-technology improvements to treat tumors with a very high accuracy, limiting the doses to the healthy tissues. This Special Issue of the Journal of Personalized Medicine focuses on the current state of interventional radiotherapy with particular attention to the clinical practice and the latest findings in the field. It will be an outlook to the innovations of brachytherapy to focus on the features mostly required in present and future clinical practice. This issue invites leading professionals in the field to share, discuss, and integrate clinical practice solutions. Therefore, we are particularly soliciting papers that feature the most exciting advances in the field of brachytherapy in clinical practice.

Guest Editors

Dr. Elisa Placidi

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy

Prof. Dr. Ángeles Rovirosa

Fonaments Clinics Dpt, Faculty of Medicine, Universitat de Barcelon, Barcelona, Spain

Deadline for manuscript submissions

closed (30 January 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/87785

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).